A new therapeutic perspective: Erastin inhibits tumor progression by driving ferroptosis in myelodysplastic syndromes
Journal of Investigative Medicine · 2024-06 · 72 (5) · 414-424
DOI: 10.1177/10815589241246541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Medicine, online erschienen am 11.05.2024. Verfasst von Jiaojiao Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Ferroptosis, Myelodysplastic Syndromes, Piperazines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Tianjin Key Medical Discipline(Specialty) Construction Project.
Abstract (Originalsprache)
Ferroptosis is a recently identified and evolutionarily conserved form of programmed cell death. This process is initiated by an imbalance in iron metabolism, leading to an overload of ferrous ions. These ions promote lipid peroxidation in the cell membrane through the Fenton reaction. As the cell’s antioxidant defenses become overwhelmed, a fatal buildup of reactive oxygen species (ROS) occurs, resulting in the rupture of the plasma membrane. Ferroptosis is implicated in conditions such as ischemia-reperfusion injuries and a range of cancers. In our research, we explored ferroptosis in myelodysplastic syndromes (MDS) by measuring iron levels, transferrin receptor expression, and glutathione peroxidase 4 (GPX4) mRNA. Our findings revealed that MDS patients had significantly higher Fe 2+ levels in CD33 + cells and increased transferrin receptor mRNA compared to healthy individuals. GPX4 expression was also higher in MDS but not statistically significant. To investigate potential treatments for myeloid hematological diseases through ferroptosis induction, we treated the myelodysplastic syndrome cell line (SKM-1) and two myeloid leukemia cell lines (KG-1 and K562) with erastin, an iron transfer inducer. We observed that erastin treatment led to glutathione depletion, reduced GPX4 activity, and increased ROS, culminating in cell death by ferroptosis. Furthermore, combining erastin with azacitidine demonstrated a synergistic effect on MDS and leukemia cell lines, suggesting a promising approach for treating these hematological conditions with this drug combination. Our experiments confirm erastin’s ability to induce ferroptosis in MDS and highlight its potential synergistic use with azacitidine for treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Medical University, Tianjin, China.
Förderung
- Tianjin Key Medical Discipline(Specialty) Construction Project
Zitieren
APA
Li, J., Ma, J., Zhang, R., Zhai, Y., Zhang, W., & Fu, R. (2024). A new therapeutic perspective: Erastin inhibits tumor progression by driving ferroptosis in myelodysplastic syndromes. Journal of Investigative Medicine, 72(5), 414-424. https://doi.org/10.1177/10815589241246541
Vancouver
Li J, Ma J, Zhang R, Zhai Y, Zhang W, Fu R. A new therapeutic perspective: Erastin inhibits tumor progression by driving ferroptosis in myelodysplastic syndromes. Journal of Investigative Medicine. 2024;72(5):414-424. doi:10.1177/10815589241246541
BibTeX
@article{Li2024,
author = {Li, Jiaojiao and Ma, Junlan and Zhang, Rui and Zhai, Yan and Zhang, Wei and Fu, Rong},
title = {A new therapeutic perspective: Erastin inhibits tumor progression by driving ferroptosis in myelodysplastic syndromes},
journal = {Journal of Investigative Medicine},
year = {2024},
volume = {72},
number = {5},
pages = {414--424},
doi = {10.1177/10815589241246541}
}
EUVIMED